InMode expects Q3 revenue between $91.8M and $92M (INMD:NASDAQ)
InMode (INMD) anticipates Q3 2026 revenue of $91.8M-$92M, with full-year revenue projected at $365M-$375M. The consensus estimates are $91.59M for Q3 and $370.27M for the year, according to the company's press release.
How this was made
The 30-second read
Why it matters
The new revenue guidance provides a fresh data point that can shift short‑term pricing.
Market read
First‑report guidance for Q3 2026, modestly above consensus, may prompt short‑term buying.
What to watch
Potential supply‑chain constraints or regulatory delays not addressed in the release.
Background
InMode is a medical‑device company providing minimally invasive aesthetic solutions.
Ticker impact
InMode issued Q3 2026 revenue guidance of $91.8M‑$92M, a fresh primary disclosure.
modest upside as market prices in the beat over consensus
The guidance exceeds the consensus $91.59M, providing new positive information for traders.
Market effects
May lift sentiment for the aesthetic medical device sector.
Limited to U.S. listed small‑cap biotech/medtech space.
Low; impact confined to InMode and close peers.
Counterpoint
Guidance still modest; if market expects higher growth, price could be pressured.
Key entities
- CompanyInMode
Medical‑device maker (NASDAQ: INMD).
